Oncolytic Virus Panels to Overcome Tumor Resistance and Antiviral Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic virus therapies face challenges such as individual variability of cancer cells, development of antiviral adaptive immunity, and resistance of cancer cells to single virus strains, leading to unpredictable therapeutic responses and potential relapses.
Innovation Solution
Administering a panel of oncolytic viruses, either sequentially or simultaneously, that differ in antigenic structure and host-cell surface receptor requirements, combined with optimized synthetic viruses to enhance specificity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a single oncolytic virus strain is used for cancer treatment, then the treatment approach is simple and cost-effective, but cancer cells may develop resistance and antiviral adaptive immunity occurs, leading to therapeutic failure
Solution Approach 1:
The treatment approach is segmented into multiple virus strains instead of using a single virus. Each virus strain targets different cancer cell characteristics or uses different entry mechanisms, ensuring that if one virus is resisted by cancer cells, other viruses can still effectively treat the cancer. This segmentation of the therapeutic approach addresses the reliability issue while maintaining manageable complexity through structured combination therapy protocols.
Solution Approach 2:
The invention uses composite viral therapy approaches where multiple different virus strains are combined to create a synergistic treatment effect. This composite approach leverages the diverse properties of different viruses (different receptor requirements, entry mechanisms, and viral genomes) to overcome cancer cell resistance mechanisms that would affect a single virus strain, thereby improving therapeutic reliability without excessive complexity.
2Reliability
If multiple oncolytic virus strains are administered simultaneously or sequentially, then the probability of overcoming cancer cell resistance and antiviral immunity increases, but the treatment complexity and potential for adverse effects increase
Solution Approach 1:
The invention employs periodic administration of different virus strains either simultaneously or sequentially at defined intervals. This periodic action allows the immune system to process and respond to each virus strain in a controlled manner, reducing the risk of severe adverse effects while maintaining high therapeutic reliability through the cyclic introduction of multiple viral agents that target different cancer cell characteristics.
Solution Approach 2:
The treatment regimen is designed to be dynamic, adapting the sequence, timing, and combination of virus strains based on patient response and tumor characteristics. This dynamic approach allows flexibility in managing treatment complexity by adjusting the regimen to individual patient needs while maintaining high reliability through personalized viral therapy selection that overcomes cancer cell resistance.
3Productivity
If oncolytic viruses are used to treat cancer, then cancer cell killing is achieved through viral replication and lysis, but development of antiviral adaptive immunity in patients leads to reduced efficacy and potential relapses
Solution Approach 1:
The viral therapy is segmented into multiple different virus strains, each with distinct antigenic structures and viral genomes. This segmentation ensures that when a patient develops antiviral adaptive immunity against one virus strain, the other virus strains in the combination can still effectively kill cancer cells. The segmented approach addresses the harmful effect of antiviral immunity while maintaining high cancer cell killing efficiency through the continued action of non-neutralized viruses.
Solution Approach 2:
The invention uses different virus strains as intermediaries that work together to achieve cancer cell killing. Each virus strain serves as an intermediary agent that can infect and lyse cancer cells through different mechanisms. This intermediary approach allows the treatment to overcome antiviral adaptive immunity by using viruses that are not targeted by pre-existing or newly formed neutralizing antibodies, thereby maintaining cancer cell killing efficiency despite the development of antiviral immunity.
Data Source
AI summary
Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors.